CYP3A4 and Hyperkalemia: In conclusion, our study found the associated risks of acute kidney injury, hyperkalemia, acute myocardial infarction, and acute ischemic stroke were higher following the coprescription of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4.